These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 27158752

  • 1. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
    Adamantia L, Antoni T.
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
    [Abstract] [Full Text] [Related]

  • 2. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.
    Rubinstein E, Corey GR, Stryjewski ME, Kanafani ZA.
    Expert Opin Pharmacother; 2011 Dec; 12(17):2737-50. PubMed ID: 22077833
    [Abstract] [Full Text] [Related]

  • 3. The clinical positioning of telavancin in Europe.
    Masterton R, Cornaglia G, Courvalin P, Lode HM, Rello J, Torres A.
    Int J Antimicrob Agents; 2015 Mar; 45(3):213-20. PubMed ID: 25600892
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.
    Hegde SS, Janc JW.
    Expert Rev Anti Infect Ther; 2014 Dec; 12(12):1463-75. PubMed ID: 25382700
    [Abstract] [Full Text] [Related]

  • 5. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S, Kuti JL, Nicolau DP.
    Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
    [Abstract] [Full Text] [Related]

  • 6. Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
    Liapikou A, Dimakou K, Toumbis M.
    Ther Adv Respir Dis; 2016 Aug; 10(4):368-78. PubMed ID: 27340253
    [Abstract] [Full Text] [Related]

  • 7. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
    Chang MH, Kish TD, Fung HB.
    Clin Ther; 2010 Dec; 32(13):2160-85. PubMed ID: 21316534
    [Abstract] [Full Text] [Related]

  • 8. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Sandrock CE, Shorr AF.
    Clin Infect Dis; 2015 Sep 15; 61 Suppl 2():S79-86. PubMed ID: 26316561
    [Abstract] [Full Text] [Related]

  • 9. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA, Nichol K, Zhanel GG.
    Clin Infect Dis; 2015 Sep 15; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [Abstract] [Full Text] [Related]

  • 10. Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections.
    Nawar T, Kanafani ZA.
    Expert Rev Anti Infect Ther; 2015 Jul 15; 13(7):825-33. PubMed ID: 26059192
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
    Barriere SL.
    Future Microbiol; 2014 Jul 15; 9(3):281-9. PubMed ID: 24450506
    [Abstract] [Full Text] [Related]

  • 13. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT, Tsuji BT.
    Pharmacotherapy; 2010 Jan 15; 30(1):80-94. PubMed ID: 20030476
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Telavancin: a new lipoglycopeptide for gram-positive infections.
    Smith WJ, Drew RH.
    Drugs Today (Barc); 2009 Mar 15; 45(3):159-73. PubMed ID: 19436839
    [Abstract] [Full Text] [Related]

  • 16. The role of telavancin in the treatment of MRSA infections in hospital.
    Bassetti M, Mikulska M, Righi E, Nicolini L, Viscoli C.
    Expert Opin Investig Drugs; 2009 Apr 15; 18(4):521-9. PubMed ID: 19335280
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM, Barriere SL, Kitt MM, Benton BM.
    Diagn Microbiol Infect Dis; 2010 Oct 15; 68(2):181-5. PubMed ID: 20846593
    [Abstract] [Full Text] [Related]

  • 18. Telavancin: a novel lipoglycopeptide antimicrobial agent.
    Attwood RJ, LaPlante KL.
    Am J Health Syst Pharm; 2007 Nov 15; 64(22):2335-48. PubMed ID: 17989443
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
    Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME, ATTAIN Study Group.
    Clin Infect Dis; 2011 Jan 01; 52(1):31-40. PubMed ID: 21148517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.